{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adult+T-cell+Lymphoma&page=2", "query": { "condition": "Adult T-cell Lymphoma", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adult+T-cell+Lymphoma&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-10T13:19:07.277Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06544265", "title": "SynKIR-310 for Relapsed/Refractory B-NHL", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "B Cell Lymphoma", "NHL, Adult", "Mantle Cell Lymphoma", "Relapsed Non-Hodgkin Lymphoma", "Refractory Non-Hodgkin Lymphoma", "Aggressive B-Cell Non-Hodgkin Lymphoma", "Indolent B-Cell Non-Hodgkin Lymphoma", "Follicular Lymphoma", "Marginal Zone Lymphoma", "DLBCL - Diffuse Large B Cell Lymphoma", "HGBL With MYC and BCL2 and/or BCL6 Rearrangements", "High-grade B-cell Lymphoma", "Diffuse Large B Cell Lymphoma", "Large B-cell Lymphoma", "T-Cell/Histiocyte Rich Lymphoma", "Non-hodgkin Lymphoma,B Cell", "Primary Mediastinal Large B-cell Lymphoma (PMBCL)", "Epstein-Barr Virus Positive DLBCL, Nos", "Follicular Lymphoma Grade 3B", "DLBCL (Diffuse Large B-Cell Lymphoma) Associated With Chronic Inflammation", "High Grade B-Cell Lymphoma, Not Otherwise Specified", "Follicular Lymphoma Grade 3", "Marginal Zone Splenic Lymphoma", "DLBCL", "Waldenstrom Macroglobulinemia", "Waldenstrom Macroglobulinaemia" ], "interventions": [ { "name": "SynKIR-310", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Verismo Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2024-11-01", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-04-14", "last_synced_at": "2026-06-10T13:19:07.277Z", "location_count": 5, "location_summary": "Denver, Colorado • Atlanta, Georgia • Fairway, Kansas + 2 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Fairway", "state": "Kansas" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06544265" }, { "nct_id": "NCT00001249", "title": "Treatment of Tac-Expressing Cutaneous T-Cell Lymphoma (CTCL) and Adult T-Cell Leukemia (ATL) With Yttrium-90 Radiolabeled Anti-Tac", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia, T-Cell", "Lymphoma, T-Cell, Cutaneous" ], "interventions": [ { "name": "Yttrium-90 radiolabeled anti-Tac antibody", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 30, "start_date": "1989-12", "completion_date": "2000-10", "has_results": false, "last_update_posted_date": "2008-03-04", "last_synced_at": "2026-06-10T13:19:07.277Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001249" }, { "nct_id": "NCT00003538", "title": "Prevention of Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "graft versus host disease prophylaxis/therapy", "type": "BIOLOGICAL" }, { "name": "allogeneic bone marrow transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "65 Years", "sex": "ALL", "summary": "Up to 65 Years" }, "enrollment_count": null, "start_date": "1997-03", "completion_date": "2004-05", "has_results": false, "last_update_posted_date": "2014-05-02", "last_synced_at": "2026-06-10T13:19:07.277Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003538" }, { "nct_id": "NCT00889408", "title": "DT2219ARL for Relapsed or Refractory CD19 (+), CD 22 (+) B-Lineage Leukemia Or Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia", "Lymphoma" ], "interventions": [ { "name": "DT2219ARL", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 25, "start_date": "2013-12-02", "completion_date": "2014-07-21", "has_results": false, "last_update_posted_date": "2017-12-02", "last_synced_at": "2026-06-10T13:19:07.277Z", "location_count": 3, "location_summary": "Minneapolis, Minnesota • Houston, Texas • Temple, Texas", "locations": [ { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Houston", "state": "Texas" }, { "city": "Temple", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00889408" }, { "nct_id": "NCT00470197", "title": "Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Relapsed or Refractory Acute Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Acute Megakaryoblastic Leukemia (M7)", "Adult Acute Minimally Differentiated Myeloid Leukemia (M0)", "Adult Acute Monoblastic Leukemia (M5a)", "Adult Acute Monocytic Leukemia (M5b)", "Adult Acute Myeloblastic Leukemia With Maturation (M2)", "Adult Acute Myeloblastic Leukemia Without Maturation (M1)", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Adult Acute Myelomonocytic Leukemia (M4)", "Adult Erythroleukemia (M6a)", "Adult Pure Erythroid Leukemia (M6b)", "Malignant Neoplasm", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia" ], "interventions": [ { "name": "alvocidib", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "mitoxantrone hydrochloride", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2007-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-09-30", "last_synced_at": "2026-06-10T13:19:07.277Z", "location_count": 2, "location_summary": "Baltimore, Maryland • Madison, Wisconsin", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT00470197" }, { "nct_id": "NCT01572493", "title": "Continuous Infusion of rhIL-15 for Adults With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma", "Carcinoma" ], "interventions": [ { "name": "rh IL-15 (10 DAYS)", "type": "BIOLOGICAL" }, { "name": "rh IL-15 (5 DAYS)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2012-04-04", "completion_date": "2019-07-02", "has_results": true, "last_update_posted_date": "2023-03-06", "last_synced_at": "2026-06-10T13:19:07.277Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01572493" }, { "nct_id": "NCT06703216", "title": "Pre-emptive Anakinra for Cytokine Event Reduction", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "B-Acute Lymphoblastic Leukemia", "CAR-T Cell Therapy", "Cytokine Release Syndrome", "Immune Effector Cell Associated Neurotoxicity Syndrome", "Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome" ], "interventions": [ { "name": "Anakinra (Kineret®)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ann & Robert H Lurie Children's Hospital of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "25 Years", "sex": "ALL", "summary": "1 Year to 25 Years" }, "enrollment_count": 24, "start_date": "2025-08", "completion_date": "2030-02-28", "has_results": false, "last_update_posted_date": "2025-06-15", "last_synced_at": "2026-06-10T13:19:07.277Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06703216" }, { "nct_id": "NCT05773040", "title": "A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphomas", "B-cell Lymphomas" ], "interventions": [ { "name": "JV-213", "type": "DRUG" }, { "name": "Leukapheresis", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2023-04-14", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-05-18", "last_synced_at": "2026-06-10T13:19:07.277Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05773040" }, { "nct_id": "NCT04195633", "title": "Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Leukemia", "Acute Lymphoblastic Leukemia", "Acute Myeloid Leukemia", "Adult Diffuse Large Cell Lymphoma", "Anaplastic Large Cell Lymphoma", "Burkitt Lymphoma", "Chronic Myeloid Leukemia, BCR-ABL1 Positive", "Chronic Myelomonocytic Leukemia", "Hodgkin Lymphoma", "Lymphoblastic Lymphoma", "Lymphoplasmacytic Lymphoma", "Mantle Cell Lymphoma", "Mixed Phenotype Acute Leukemia", "Myelodysplastic Syndrome", "Prolymphocytic Leukemia", "Refractory Chronic Lymphocytic Leukemia", "Refractory Follicular Lymphoma", "Refractory Marginal Zone Lymphoma", "Refractory Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "Allogeneic Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Filgrastim", "type": "BIOLOGICAL" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Mycophenolate Sodium", "type": "DRUG" }, { "name": "Total-Body Irradiation", "type": "RADIATION" }, { "name": "Treosulfan", "type": "DRUG" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL", "RADIATION" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "6 Months", "maximum_age": null, "sex": "ALL", "summary": "6 Months and older" }, "enrollment_count": 60, "start_date": "2021-01-25", "completion_date": "2029-03-12", "has_results": false, "last_update_posted_date": "2026-05-29", "last_synced_at": "2026-06-10T13:19:07.277Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT04195633" }, { "nct_id": "NCT00006340", "title": "Ganciclovir Plus Arginine Butyrate in Treating Patients With Cancer or Lymphoproliferative Disorders Associated With the Epstein Barr Virus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia", "Lymphoma", "Precancerous Condition", "Small Intestine Cancer" ], "interventions": [ { "name": "arginine butyrate", "type": "DRUG" }, { "name": "ganciclovir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boston Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": null, "sex": "ALL", "summary": "3 Years and older" }, "enrollment_count": null, "start_date": "1994-12", "completion_date": "2000-07", "has_results": false, "last_update_posted_date": "2013-07-26", "last_synced_at": "2026-06-10T13:19:07.277Z", "location_count": 3, "location_summary": "Indianapolis, Indiana • Boston, Massachusetts • New York, New York", "locations": [ { "city": "Indianapolis", "state": "Indiana" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006340" } ] }